Table 2.

Overview of COVID-19 therapies under investigation

Antiviral interventions

Monoclonal antibodies

Bamlanivimab 700 mg/etesevimab 1400 mg

Casirivimab 600 mg/imdevimab 600 mg

Sotrovimab 500 mg

Small molecule antivirals

Remdesivir

Molnupiravir

Paxlovid

Interventions for the inflammatory response phase

Corticosteroids

Interleukin-6 receptor antagonists: tocilizumab and sarilumab

Janus kinase inhibitors: baricitinib and tofacitinib

Interleukin-1 receptor antagonist: anakinra

Anti-GM-CSF monoclonal antibodies

Interferon beta-1a

COVID-19, coronavirus disease 2019; GM-CSF, granulocyte-macrophage colony-stimulating factor.